Publications by authors named "G Chakraborty"

The present study investigates the effect of ultrasonication (US) amplitude (30 %, 50 %, and 70 %, time- 45 min) followed by octenyl succinic anhydride (OSA, 3 %) esterification on morphological, structural, functional, and rheological properties of sorghum starch. The increase in US amplitudes significantly (p < 0.05) increased the degree of substitution (DS) of esterified starch (0.

View Article and Find Full Text PDF

Tributyl phosphate (TBP), an organophosphate ester (OPE), is heavily used as a solvent in chemical industries, a plasticizer, and to extract radioactive molecules. Thus, widespread uses of TBP in industrialized countries led to the release of TBP and its metabolites, dibutyl phosphate (DBP) and monobutyl phosphate (MBP), in the environment and were detected in human samples. Accumulating these OPEs over time in humans and aquatic animals may develop toxicological effects.

View Article and Find Full Text PDF

Despite notable advancements in cancer therapy, it remains a formidable global health challenge. The emergence of combinational treatments, particularly the integration of chemotherapy with photodynamic therapy (chemo-PDT), offers a glimmer of hope. This study introduces the development of zinc-coordinated quercetin-based self-assembled nanoparticles (ZnQ NPs) for advanced dual-mode cancer therapy.

View Article and Find Full Text PDF
Article Synopsis
  • * PARP inhibitors (PARPi) are emerging as a treatment for mCRPC patients with specific genetic alterations, functioning by trapping PARP to increase DNA damage and induce cell death; however, their effectiveness typically wanes after 3-4 months due to the development of resistance.
  • * Resistance mechanisms to PARPi include mutations in DNA repair genes and pathways that restore DNA repair capabilities; strategies to overcome this resistance involve combining PARPi with other treatments or targeting different signaling pathways.
View Article and Find Full Text PDF

Oral Squamous cell carcinoma (OSCC) is the 14th most frequent cancer with 300,000 new cases and 100,000 deaths reported annually. Even with advanced therapy, the treatment outcomes are poor at advanced stages of the disease. The diagnosis of early OSCC is of paramount clinical value given the high mortality rate associated with the late stages of the disease.

View Article and Find Full Text PDF